Associations Between Low-Value Medication in Dementia and Healthcare Costs

• DOI: 10.1007/s40261-022-01151-9
• Publication Date: 2022-04-28T05:02:48Z
• Authors: Moritz Platen; Steffen Flessa; Anika Rädke; Diana Wucherer; Jochen René Thyrian; Annelie Scharf; Wiebke Mohr; Franka Mühlichen; Wolfgang Hoffmann; Bernhard Michalowsky
• Keywords: drug therapy [Dementia]; Health Care Costs; 3. Good health; 03 medical and health sciences; Cross-Sectional Studies; 0302 clinical medicine; Caregivers; Medical and Health Sciences ; Dementia/drug therapy [MeSH] ; Humans [MeSH] ; Caregivers [MeSH] ; Original Research Article ; Retrospective Studies [MeSH] ; Cross-Sectional Studies [MeSH] ; Health Care Costs [MeSH]; Humans; Dementia; ddc:610; Original Research Article; Retrospective Studies

Low-value medications (Lvm) provide little or no benefit to patients, may be harmful, and waste healthcare resources costs. Although evidence from the literature indicates that Lvm is highly prevalent in dementia, about financial consequences of dementia limited. This study analyzed association between receiving costs a public payers' perspective.